Across TCGA pan-cancer cohorts, TRAV34 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV34 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher TRAV34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV34 expression acts as an unfavorable survival marker.

SARC and PRAD are the cancer types where TRAV34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAV34 tumor-vs-normal RNA expression · all TRAV34 data types